Intra-ImmuSG seeks to develop a safer and more effective cancer therapy via a combination of a targeted therapy and immunotherapy.

Nektar Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric patients 12 years ...